Background characteristics and anticoagulant usage patterns of elderly
non-valvular atrial fibrillation patients in the ANAFIE registry: a prospective,
multicentre, observational cohort study in Japan.
Yasaka M(1), Yamashita T(2), Akao M(3), Atarashi H(4), Ikeda T(5), Koretsune Y(6), Okumura K(7), Shimizu W(8), Tsutsui H(9), Toyoda K(10), Hirayama A(11), Yamaguchi T(10), Teramukai S(12), Kimura T(13), Kaburagi J(14), Takita A(15), Inoue H(16). Author information:
(1)Department of Cerebrovascular and Neurology, National Hospital Organization
Kyushu Medical Center, Fukuoka, Japan [Email]
(2)Department of Cardiovascular Medicine, The Cardiovascular Institute, Tokyo,
(3)Department of Cardiology, National Hospital Organization Kyoto Medical
Center, Kyoto, Japan.
(4)Minami Hachioji Hospital, Tokyo, Japan.
(5)Department of Cardiovascular Medicine, Toho University Omori Medical Center,
(6)Institute for Clinical Research, National Hospital Organization, Osaka
National Hospital, Osaka, Japan.
(7)Division of Cardiology, Saiseikai Kumamoto Hospital, Kumamoto, Japan.
(8)Department of Cardiovascular Medicine, Nippon Medical School, Tokyo, Japan.
(9)Department of Cardiovascular Medicine, Kyushu University, Fukuoka, Japan.
(10)National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.
(11)Osaka Police Hospital, Osaka, Japan.
(12)Department of Biostatistics, Kyoto Prefectural University of Medicine,
(13)Medical Science Department, Daiichi Sankyo Co., Ltd, Tokyo, Japan.
(14)ASCA Company, Daiichi Sankyo Co., Ltd, Tokyo, Japan.
(15)Data Intelligence Department, Daiichi Sankyo Co., Ltd, Tokyo, Japan.
(16)Saiseikai Toyama Hospital, Toyama, Japan.
OBJECTIVE: To explore anticoagulant usage patterns stratified by stroke and bleeding risk in elderly patients with non-valvular atrial fibrillation (NVAF). DESIGN: Prospective, multicentre, observational cohort study. SETTING: The real-world All Nippon AF In the Elderly (ANAFIE) registry. PARTICIPANTS: Japanese patients aged ≥75 years with NVAF (n=32 726). OUTCOME MEASURES: The distribution of stroke and bleeding risk scores, and the selection of anticoagulant regimen for patients at high stroke and bleeding risk. RESULTS: Overall, 18 185 (55.6%) patients had a high risk of stroke (CHADS2 score ≥3). Of these, 12 561 (38.4% of the total ANAFIE population) had a low bleeding risk (HAS-BLED ≤2) and 5624 (17.2%) had a high bleeding risk (HAS-BLED ≥3). Significant differences were noted between the high versus low bleeding risk groups in sex, height, weight, systolic blood pressure and rates of abnormality of lipid metabolism, gastrointestinal disease, cerebrovascular disorders, chronic kidney disease, angina pectoris, respiratory disease, primary malignant tumour, dementia and fall history within the past year (all p<0.0001). Patients with high stroke and bleeding risks had a lower anticoagulant usage rate versus the low bleeding risk group, and 8.7% and 5.8%, respectively, were not receiving any anticoagulant (p<0.0001). Patients in the high bleeding risk group had a higher usage of warfarin versus the low bleeding risk group (p<0.0001); more patients (14.0%) in the high bleeding risk group receiving warfarin had time in the therapeutic range <40%, versus those in the low bleeding risk group (11.6%, p=0.0146). Direct-acting oral anticoagulants (DOACs) were used less in the high bleeding risk group, without notable differences in the DOAC dose distribution between the two groups. CONCLUSIONS: In elderly NVAF patients at high stroke risk, significant demographic and clinical differences were observed according to bleeding risk. Administration of low-dose DOACs was frequent, but the dose distribution was unaffected by bleeding risk. TRIAL REGISTRATION NUMBER: UMIN000024006 (http://www.umin.ac.jp/).
Having over 250 Research scholars worldwide and more than 400 articles online with open access.